Evergreen Wealth Management LLC Acquires 14,450 Shares of Johnson & Johnson (NYSE:JNJ)

Evergreen Wealth Management LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 142.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,617 shares of the company’s stock after acquiring an additional 14,450 shares during the quarter. Johnson & Johnson accounts for about 2.4% of Evergreen Wealth Management LLC’s portfolio, making the stock its 16th largest position. Evergreen Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,990,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. China Universal Asset Management Co. Ltd. bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $765,000. Empowered Funds LLC grew its holdings in Johnson & Johnson by 46.7% during the 1st quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock worth $16,015,000 after acquiring an additional 32,244 shares during the last quarter. Alpha Family Trust grew its holdings in Johnson & Johnson by 180.0% during the 1st quarter. Alpha Family Trust now owns 6,230 shares of the company’s stock worth $986,000 after acquiring an additional 4,005 shares during the last quarter. Kingsview Wealth Management LLC lifted its position in shares of Johnson & Johnson by 1.1% in the 1st quarter. Kingsview Wealth Management LLC now owns 137,942 shares of the company’s stock worth $21,821,000 after purchasing an additional 1,559 shares during the period. Finally, Maple Capital Management Inc. lifted its position in shares of Johnson & Johnson by 2.8% in the 1st quarter. Maple Capital Management Inc. now owns 161,137 shares of the company’s stock worth $25,490,000 after purchasing an additional 4,330 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on JNJ shares. Wolfe Research started coverage on shares of Johnson & Johnson in a research report on Friday. They issued an “outperform” rating and a $190.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Guggenheim boosted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Finally, Citigroup boosted their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $175.94.

Johnson & Johnson Stock Up 1.4 %

Shares of JNJ stock traded up $2.13 during mid-day trading on Friday, reaching $154.00. 11,328,515 shares of the company’s stock traded hands, compared to its average volume of 7,017,128. The company’s 50-day moving average price is $161.35 and its 200-day moving average price is $156.02. The company has a market cap of $370.77 billion, a P/E ratio of 22.29, a P/E/G ratio of 2.72 and a beta of 0.53. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.66 EPS. On average, equities analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.22%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.